92 related articles for article (PubMed ID: 20675896)
1. The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury.
Liuni A; Luca MC; Gori T; Parker JD
Clin Hemorheol Microcirc; 2010; 45(2-4):161-7. PubMed ID: 20675896
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism.
Liuni A; Luca MC; Gori T; Parker JD
J Am Coll Cardiol; 2010 Mar; 55(10):1002-6. PubMed ID: 20202516
[TBL] [Abstract][Full Text] [Related]
3. Short-term statin treatment does not prevent ischemia and reperfusion-induced endothelial dysfunction in humans.
Wouters CW; Wever KE; Bronckers I; Hopman MT; Smits P; Thijssen DH; Rongen GA
J Cardiovasc Pharmacol; 2012 Jan; 59(1):22-8. PubMed ID: 21885990
[TBL] [Abstract][Full Text] [Related]
4. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion.
Joyce M; Kelly C; Winter D; Chen G; Leahy A; Bouchier-Hayes D
J Surg Res; 2001 Nov; 101(1):79-84. PubMed ID: 11676559
[TBL] [Abstract][Full Text] [Related]
5. Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension.
Matsuo S; Saiki Y; Adachi O; Kawamoto S; Fukushige S; Horii A; Saiki Y
J Thorac Cardiovasc Surg; 2015 Mar; 149(3):902-9. PubMed ID: 25454916
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts.
Di Napoli P; Taccardi AA; Grilli A; De Lutiis MA; Barsotti A; Felaco M; De Caterina R
Cardiovasc Res; 2005 Jun; 66(3):462-71. PubMed ID: 15914111
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury.
Ke D; Fang J; Fan L; Chen Z; Chen L
Coron Artery Dis; 2013 Jun; 24(4):334-41. PubMed ID: 23531479
[TBL] [Abstract][Full Text] [Related]
9. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor.
Jones SP; Gibson MF; Rimmer DM; Gibson TM; Sharp BR; Lefer DJ
J Am Coll Cardiol; 2002 Sep; 40(6):1172-8. PubMed ID: 12354446
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
Laufs U; Gertz K; Dirnagl U; Böhm M; Nickenig G; Endres M
Brain Res; 2002 Jun; 942(1-2):23-30. PubMed ID: 12031849
[TBL] [Abstract][Full Text] [Related]
11. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
Landsberger M; Jantzen F; Könemann S; Felix SB
Biochem Biophys Res Commun; 2005 Nov; 336(4):1005-9. PubMed ID: 16165089
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.
Verhulst A; D'Haese PC; De Broe ME
J Am Soc Nephrol; 2004 Sep; 15(9):2249-57. PubMed ID: 15339974
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits.
D'Annunzio V; Donato M; Erni L; Miksztowicz V; Buchholz B; Carrión CL; Schreier L; Wikinski R; Gelpi RJ; Berg G; Basso N
J Cardiovasc Pharmacol; 2009 Feb; 53(2):137-44. PubMed ID: 19188835
[TBL] [Abstract][Full Text] [Related]
14. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
Stalker TJ; Lefer AM; Scalia R
Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
[TBL] [Abstract][Full Text] [Related]
15. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose.
Piconi L; Corgnali M; Da Ros R; Assaloni R; Piliego T; Ceriello A
J Diabetes Complications; 2008; 22(1):38-45. PubMed ID: 18191076
[TBL] [Abstract][Full Text] [Related]
16. Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study.
Liuni A; Luca MC; Gori T; Parker JD
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H153-8. PubMed ID: 22003053
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation.
Bulhak A; Roy J; Hedin U; Sjöquist PO; Pernow J
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3158-63. PubMed ID: 17322412
[TBL] [Abstract][Full Text] [Related]
18. Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor.
Hanefeld M
Int J Clin Pract; 2001; 55(6):399-405. PubMed ID: 11501230
[TBL] [Abstract][Full Text] [Related]
19. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Kilic U; Bassetti CL; Kilic E; Xing H; Wang Z; Hermann DM
Neuroscience; 2005; 134(3):901-6. PubMed ID: 16009498
[TBL] [Abstract][Full Text] [Related]
20. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M
J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
